Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Le Gars

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Vaccines|October 26, 2024
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical TrialVeronica V Rezelj, Fred Paddenburg, Marie Enajite Diegbe, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Human Vaccines & Immunotherapeutics|March 28, 2022
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of ageAnna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, et al.
American Journal of Respiratory and Critical Care Medicine|December 11, 2012
Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivoMathieu Le Gars, Delphyne Descamps, Delphine Roussel, et al.
Frontiers in Immunology|November 12, 2019
Pregnancy-Induced Alterations in NK Cell Phenotype and FunctionMathieu Le Gars, Christof Seiler, Alexander W Kay, et al.
The Lancet. Infectious Diseases|September 16, 2022
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, An Vandebosch, Jerald Sadoff, et al.
The New England Journal of Medicine|July 14, 2021
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S VaccinationDan H Barouch, Kathryn E Stephenson, Jerald Sadoff, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19Dan H Barouch, Kathryn E Stephenson, Jerald Sadoff, et al.
Ebiomedicine|June 15, 2025
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trialNina Hertoghs, Sanne Roels, Matthias Brückner, et al.
Iscience|April 24, 2024
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.SCatherine Jacob-Dolan, Michelle Lifton, Olivia C Powers, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Vaccines|October 26, 2024
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical TrialVeronica V Rezelj, Fred Paddenburg, Marie Enajite Diegbe, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Human Vaccines & Immunotherapeutics|March 28, 2022
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of ageAnna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, et al.
American Journal of Respiratory and Critical Care Medicine|December 11, 2012
Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivoMathieu Le Gars, Delphyne Descamps, Delphine Roussel, et al.
Frontiers in Immunology|November 12, 2019
Pregnancy-Induced Alterations in NK Cell Phenotype and FunctionMathieu Le Gars, Christof Seiler, Alexander W Kay, et al.
The Lancet. Infectious Diseases|September 16, 2022
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, An Vandebosch, Jerald Sadoff, et al.
The New England Journal of Medicine|July 14, 2021
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S VaccinationDan H Barouch, Kathryn E Stephenson, Jerald Sadoff, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19Dan H Barouch, Kathryn E Stephenson, Jerald Sadoff, et al.
Ebiomedicine|June 15, 2025
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trialNina Hertoghs, Sanne Roels, Matthias Brückner, et al.
Iscience|April 24, 2024
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.SCatherine Jacob-Dolan, Michelle Lifton, Olivia C Powers, et al.
Pageof 5